Pharma Capital

Dimerix's Kathy Harrison discusses pending Phase 2 clinical trials

Kathy Harrison, chief executive officer for Dimerix, speaks with Proactive Investors.

 

View full DXB profile

Dimerix Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.